Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DEVICE: Epicutaneous cryoimmunotherapy|DRUG: Topical imiquimod|DRUG: Pembrolizumab|OTHER: Dermatologic Quality of Life Index|OTHER: Functional Assessment of Cancer Therapy|DRUG: Intra-lesional GM-CSF|DEVICE: Cry-AC|PROCEDURE: Cutaneous tumor biopsy|PROCEDURE: Peripheral blood draw for research
Sponsor: Washington University School of Medicine
Collaborators: Merck Sharp & Dohme LLC